Evidence map›Paper›PMID 40323513›Full record

ArticleInternational journal of clinical oncology2025

Contrast-enhanced ultrasound imaging characteristics of intrahepatic cholangiocarcinoma with actionable gene variants detected by comprehensive cancer gene panel testing.

Kazunori Nakaoka, Eizaburo Ohno, Seiji Yamada, Teiji Kuzuya, Tamotsu Sudo, Sayaka Ueno, Hiroyuki Tanaka, Yutaka Sasaki, Ryoji Miyahara, Senju Hashimoto and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kazunori NakaokaDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.ORCID http://orcid.org/0000-0002-7407-1763
Eizaburo OhnoDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Seiji YamadaDivision of Analytical PathologyOncology Invitation Center, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Teiji KuzuyaDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Tamotsu SudoDepartment of Cancer Genetics and Genomics, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Sayaka UenoDepartment of Cancer Genetics and Genomics, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Hiroyuki TanakaDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Yutaka SasakiDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Ryoji MiyaharaDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Senju HashimotoDepartment of Gastroenterology, Fujita Health University Bantane Hospital, Nakagawa-ku, OtoubashiNagoya, Aichi, Japan.
Yoshiki HirookaDepartment of Gastroenterology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. yoshiki.hirooka@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0001-9639-7425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer gene panel testing (CGP) helps comprehensively analyze a large number of genes, extracting genetic information from the genome profile to aid treatment plans and drug therapy. Advances in drug therapy and surgical treatment for intrahepatic cholangiocarcinoma (ICC) have improved patient outcomes; however, it remains a typical intractable cancer with a poor prognosis. ICC is one of the key tumors for which effective treatment may be identified through CGP testing. This study aimed to identify ICC harboring actionable genetic variants using contrast-enhanced ultrasonography (CE-US).

methodsWe enrolled 26 ICC patients who underwent CE-US before chemotherapy or surgery. Three ultrasound specialists reviewed the images by consensus and assessed the imaging features, including vascularity. Pathological data were reviewed after diagnosis using CE-US. We retrospectively analyzed distinctive CE-US findings in patients with ICC with actionable genetic variants.

resultsTwelve ICC patients had actionable gene variants, including four FGFR2 fusions, one FGFR2 rearrangement, six IDH1 mutations, and one BRAF V600E mutation. Univariate analysis showed significant differences in bile duct invasion (p = 0.0217) and blood vessel penetration within the tumor (p = 0.0012). Multivariable logistic regression identified blood vessel penetration within the tumor (OR = 18.275; 95% CI: 1.331-250.925; p = 0.0297) as independently associated with actionable gene variants.

conclusionPatients with ICC and blood vessel penetration on CE-US should be considered for CGP testing.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaAdultAgedContrast MediaFemaleGenetic TestingHumansMaleMiddle AgedMutationRetrospective StudiesUltrasonographyContrast MediaBlood vessel penetrationComprehensive cancer gene panelContrast-enhanced transabdominal ultrasonographyIntrahepatic cholangiocarcinoma

Identifiers

PMID40323513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.